Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark – the SHADE

Table 2 Prevalence of high-risk human papillomavirus (HPV) in women with sufficient DNA for analyses in women living with HIV compared to women matched (1:5) on prior screening history and age from the general Danish population

	Women living with HIV 295	Women from the general population 1,475	p-value
High-risk HPV positive, n(%)
Yes	78 (26.4)	245 (16.6)	<0.0001
No	217 (73.6)	1,230 (83.4)	<0.0001
Number of genotypes, mean (range)	1.54 (1–4)	1.38 (1–5)	0.047
Number of infections, n(%)
Single	48 (61.5)	182 (74.3)	0.030
Multiple (>1)	30 (38.5)	63 (25.7)	0.030
All high-risk genotypes present targeted by the 4-valent HPV vaccine^a, n(% of the HPV positive patients)
Yes	8 (10.3)	52 (21.2)	0.030
No	70 (89.7)	193 (78.8)	0.030
All high-risk genotypes present targeted by the 9-valent vaccine^b, n(% of the HPV positive patients)
Yes	42 (53.9)	155 (63.3)	0.14
No	36 (46.1)	90 (36.7)	0.14
Presence of ≥1 high-risk genotypes targeted by the 4-valent vaccine^a, n(% of the HPV positive patients)
Yes	21 (26.9)	76 (31.0)	0.49
No	57 (73.1)	169 (69.0)	0.49
Presence of ≥1 high-risk genotypes targeted by the 9-valent vaccine^b, n(% of the HPV positive patients)
Yes	61 (78.2)	194 (79.2)	0.85
No	17 (21.8)	51 (20.8)	0.85

^aTargeting HPV6, HPV11, HPV16 and HPV18. HPV6 and HPV11 are low-risk genotypes and not included in this analysis
^bTargeting HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58. HPV6, and HPV11 are low-risk genotypes and not included in this analysis

ISSN: 1471-2407